Skip to main content

Ali Asif's Form 4 filing

Protagonist Therapeutics, Inc (PTGX) · filed Jan 27, 2026

Accession no.
0001104659-26-007128
Filed
Jan 27, 2026
Trade date
Jan 27, 2026
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.84M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ali AsifCIK 0001921163Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 27, 2026Common StockMOption exerciseAcquired+16,000$19.19+$307,04094,523Direct
Jan 27, 2026Common StockMOption exerciseAcquired+12,000$12.17+$146,040106,523Direct
Jan 27, 2026Common StockSSaleDisposed−28,000$83.13−$2,327,64078,523Direct
Jan 27, 2026Common StockSSaleDisposed−18,203$83.14−$1,513,397.4260,320Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 27, 2026Common StockMOption exerciseDisposed−16,000$0.00$050,800Direct
Jan 27, 2026Common StockMOption exerciseDisposed−12,000$0.00$018,547Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)